Redox Biology (Aug 2017)

Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation

  • Yu Yeon Jung,
  • Dong Ju Son,
  • Hye Lim Lee,
  • Dae Hwan Kim,
  • Min Jong Song,
  • Young Wan Ham,
  • Youngsoo Kim,
  • Sang Bae Han,
  • Mi Hee Park,
  • Jin Tae Hong

Journal volume & issue
Vol. 12
pp. 666 – 673

Abstract

Read online

Parkin is associated with various inflammatory diseases, including Parkinson's disease (PD) and rheumatoid arthritis (RA). However, the precise role of Parkin in RA is unclear. The present study addressed this issue by comparing the development of RA between non-transgenic (non-Tg) mice and PARK2 knockout (KO) mice. We found that cyclooxygenase-2 and inducible nitric oxide synthase expression and nuclear factor-κB activity were reduced but p53 activation was increased in PARK2 KO as compared to non-Tg mice. These effects were associated with reduced p53 degradation. Parkin was found to interact with p53; however, this was abolished in Parkin KO mice, which prevented p53 degradation. Treatment of PARK2 KO mice with p53 inhibitor increased Parkin expression as well as inflammation and RA development while decreasing nuclear p53 translocation, demonstrating that PARK2 deficiency inhibits inflammation in RA via suppression of p53 degradation. These results suggest that RA development may be reduced in PD patients. Keywords: Parkin, Arthritis, p53, Ubiquitination